Please login to the form below

Not currently logged in
Email:
Password:

Constitution Medical Investors

This page shows the latest Constitution Medical Investors news and features for those working in and with pharma, biotech and healthcare.

Roche pays $220m for blood-testing company

Roche pays $220m for blood-testing company

Boosts diagnostics business with acquisition of Constitution Medical Investors. The Bloodhound system to diagnose haematological conditions. ... Roche said yesterday it is to acquire Constitution Medical Investors (CMI), which markets a system to

Latest news

  • Roche's blood cancer antibody wins priority review in US Roche's blood cancer antibody wins priority review in US

    Roche has also boosted its efforts in the diagnosis of blood disorders, such as leukaemia, with the purchase of Constitution Medical Investors and its 'Bloodhound' technology to provide fast, accurate analysis ... Hal Barron, chief medical office of Roche

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Acthar complements Mallinckrodt's portfolio of specialty pharmaceutical brands which include Exalgo, Gablofen, Pennsaid and Xartemis and reduces the company's focus on medical imaging and pain drugs. ... In recent years Roche has signed a string of deals

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics